Nebulization of risedronate alleviates airway obstruction and inflammation of chronic obstructive pulmonary diseases via suppressing prenylation-dependent RAS/ERK/NF-κB and RhoA/ROCK1/MLCP signaling
Liu D, Xu W, Tang Y, Cao J, Chen R, Wu D, Chen H, Su B, Xu J. Nebulization of risedronate alleviates airway obstruction and inflammation of chronic obstructive pulmonary diseases via suppressing prenylation-dependent RAS/ERK/NF-κB and RhoA/ROCK1/MLCP signaling. Respiratory Research 2022, 23: 380. PMID: 36575527, PMCID: PMC9795678, DOI: 10.1186/s12931-022-02274-5.Peer-Reviewed Original ResearchConceptsAirway smooth muscle cellsAirway obstructionB2 agonistsObstructive pulmonary diseaseLung inflammationCOPD ratsInflammation of chronic obstructive pulmonary diseaseExpression of B2 receptorsLung depositionPulmonary diseaseTumor necrosis factor-alphaFirst-line treatmentNecrosis factor-alphaTreating COPD patientsChronic obstructive pulmonary diseaseSmooth muscle cellsTreatment of COPDBackgroundChronic obstructive pulmonary diseaseNitrogen-containing bisphosphonatesProgression of COPDLung function declineLong-term useRisedronate treatmentASMCs relaxationAntimuscarinic drugs